BROADCASTS.com

In today's episode of our news analysis show 16 Minutes, our topic is the ongoing buzz and the mixed news around the Johnson & Johnson vaccine, which was the third vaccine for COVID approved under Emergency Use Authorization by the FDA just a few weeks ago. Johnson & Johnson reported it as \u201cthe first single shot vaccine\u201d and as having 85% efficacy in preventing severe disease across regions studied; meanwhile, STAT headlines reported 66% efficacy overall and 72% in the U.S. in preventing moderate to severe disease, calling it \u201ca weapon but not a knockout punch.\u201d And then we have various experts saying everything from \u201cdisappointing\u201d to pointing out the dangers of comparing this vaccine to other vaccines such as Pfizer\u2019s and Moderna\u2019s, both of which we\u2019ve talked about on this show. You can find all our ongoing vaccines coverage at a16z.com/vaccines.\xa0\xa0\n\nIn this episode \u2014 since 16 Minutes is about teasing apart what\u2019s hype/ what\u2019s real in the news and where we are on the long arc of innovation \u2014 we asked the a16z bio team for their frameworks.\xa0\n\nJoining us are General Partner Jorge Conde, who has been in all our vaccine episodes and previously led strategy and product for a\xa0 pharmaceuticals company, and bio editorial partner Lauren Richardson, who was previously an editor at PLOS Biology and hosts our sister show Journal Club on Bio Eats World. She also holds a Ph.D in pharmacology.